The estimated Net Worth of Enterprise Associates 14, L... is at least $3.54 millió dollars as of 23 April 2018. Enterprise L owns over 133,333 units of Surface Oncology Inc stock worth over $3,544,778 and over the last 9 years Enterprise sold SURF stock worth over $0.
Enterprise has made over 2 trades of the Surface Oncology Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Enterprise bought 133,333 units of SURF stock worth $1,999,995 on 23 April 2018.
The largest trade Enterprise's ever made was buying 857,142 units of Surface Oncology Inc stock on 5 October 2015 worth over $5,999,994. On average, Enterprise trades about 198,095 units every 186 days since 2015. As of 23 April 2018 Enterprise still owns at least 3,312,877 units of Surface Oncology Inc stock.
You can see the complete history of Enterprise L stock trades at the bottom of the page.
Enterprise's mailing address filed with the SEC is 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM, MD, 21093.
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: